Exclusive Distribution Agreement Announced Welch Allyn and LKC Technologies announce an exclusive distribution agreement for RETeval DR visual electrodiagnostic system

Skaneateles Falls, NY, November 12, 2014 —Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, and LKC Technologies, Inc., the worldwide leader in visual electrophysiology and inventor of the RETeval® DR diabetic retinopathy assessment device today announced that they have entered into an exclusive distribution agreement. Under the terms of the agreement, Welch Allyn will distribute the RETeval DR to healthcare providers outside of the United States who are focused on diabetic patients who face increased risk of sight-threatening disease such as diabetic retinopathy.

Diabetic retinopathy (DR) is the leading cause of blindness among working-age adults1. Yet DR is one of the most preventable blinding diseases in the world. With early detection, DR can be treated and the risk of severe vision loss decreased by more than 90%2 . Unfortunately, half of diabetic patients do not get annual retinal exams3 due to either lack of access to specialist care and/or lack of compliance with their doctor’s referral.

The RETeval DR provides a simple, fast, accurate, and cost-effective way to screen for severe diabetic retinopathy without leaving the primary care office—compared to the current standard of care which is referral to the ophthalmologist or optometrist for a retinal exam using direct and indirect ophthalmoscopy, and/or mydriatic or nonmydriatic color fundus photography.

“We are very excited to partner with LKC Technologies to distribute this absolutely unique device,” said Thomas Grant, director of New Healthcare Delivery Solutions at Welch Allyn. “RETeval DR has the potential to reduce the impact of vision-threatening diabetic retinopathy by increasing access to, and compliance with, regular retinal screens for people with diabetes.”

Data from a 468-patient multi-site clinical trial at the U.S. Veteran’s Administration Medical Centers in Oklahoma City and Atlanta this year showed the RETeval DR is able to reliably predict disease— clinically significant macular edema (CSME), severe non-prolific diabetic retinopathy (NPDR), or prolific diabetic retinopathy (PDR). In a screening setting for diabetics (with NHANES 2005-2008 prevalence), RETeval would suggest 76% do NOT need to be referred and would be correct 99% of the time.

“We have an opportunity to make a real impact in the lives of diabetics globally,” said James Datovech, president of LKC Technologies. “According to International Diabetes Federation data, seventy percent of 350 million diabetics live in low- to middle-income regions that may not have ready access to eye specialists or technology such as fundus cameras that are effective but expensive and bulky. RETeval DR is handheld, very portable, and screening can be done in less than five minutes enabling far greater reach and clinical impact compared to current methods.”

RETeval DR will be available from Welch Allyn in most countries outside the U.S. in the first quarter of 2015. The RETeval Complete product, which is useful for a broader range of ocular diseases and conditions, will remain exclusive to LKC Technologies worldwide. The RETeval DR and RETeval Complete products are not yet available in the U.S.

About Welch Allyn, Inc.

Welch Allyn provides innovative solutions to help reduce risk and improve patient safety, satisfaction and outcomes in a variety of clinical settings through a complete range of EMR-interfaced vital signs and cardiac monitoring diagnostic solutions, physical diagnosis instruments, and infection control products. The company specializes in helping doctors, nurses and other frontline providers across the globe streamline workflow by developing cutting edge products that enable immediate access to accurate patient data. A leading global healthcare company founded in 1915 and headquartered in Skaneateles Falls, N.Y. (USA), Welch Allyn is a family-owned business that employs nearly 2,600 employees in 26 different countries. More information about Welch Allyn and its complete line of connected products and solutions may be found at www.welchallyn.com. Like us on Facebook and follow us on Twitter and LinkedIn.

About LKC Technologies, Inc.

LKC Technologies, Inc. is the worldwide leader in the visual electrophysiology field with products in over fifty countries. LKC’s products are used to diagnose a large number of ophthalmic conditions by measuring evoked potentials, including ERG, EOG, and VEP, dark adaptometry and more. LKC is dedicated to delivering a constantly-improving, high-quality product and offering top-of-the-line service to our customers. LKC Technologies, Inc. is a privately-owned company with a thirty-eight year history of serving the visual electrophysiology needs of its customers. Visit www.lkc.com for more information.

 

1 Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med 2013; 30: 387-398.
2 American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2008:7.
3 Centers for Disease Control and Prevention. National Center for Health Statistics. Health Indicators Warehouse.